Last reviewed · How we verify

NCT04084327

Immunophenotyping of Acute b Cell Lymphoblstic Leukemia

Status unknown Last updated 10 September 2019
What this trial tests

trial testing stastical analysis in Acute Leukemia in 50 participants. Status unknown.

Timeline
1 September 2019
Primary endpoint
1 December 2020
1 December 2022

Quick facts

Lead sponsorSouth Egypt Cancer Institute
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment50
Start date1 September 2019
Primary completion1 December 2020
Estimated completion1 December 2022

Drugs / interventions tested

Conditions studied

Sponsor

South Egypt Cancer Institute

Who can join

Adults 12 Months to 80, any sex, with Acute Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To study the immunophenotyping pattern of acute B lymphoblastic leukemia in south Egypt Cancer Institute iand its correlation with disease outcome

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Leukemia

Currently open trials in the same condition.

Other South Egypt Cancer Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04084327.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing